


| | | |
|---|--|------------------------|
| INFORMATION DISCLOSURE STATEMENT | Docket No. 27693-01009 | Serial No: 09/ 911,692 |
| | Inventor(s): D.R. ANDERSON <i>et al.</i> | Examiner: R. Schwadron |
| | Filed: 25 July 2001 | Art Unit: 1644 |

U.S. PATENT DOCUMENTS

| INITIAL | INDEX | DOCUMENT | DATE | NAME | CLASS | SUB. | FILING DATE |
|---------|-------|------------------|-------------|----------|-------|------|-------------|
| WBS | D1 | 4,831,175 | 16 May 1989 | Gansow | — | — | |
| | D2 | 5,099,069 | 24 Mar 1992 | Gansow | — | — | |
| | D3 | 5,124,471 | 23 Jun 1992 | Gansow | — | — | |
| | D4 | 5,246,692 | 21 Sep 1993 | Gansow | — | — | |
| | D5 | 5,286,850 | 15 Feb 1994 | Gansow | — | — | |
| | D6 | 5,460,785 | 24 Oct 1995 | Rhodes | — | — | |
| | D7 | 2003/ 0095963 A1 | 22 May 2003 | Anderson | — | — | |
| | D8 | 2004/ 0167319 A1 | 26 Aug 2004 | Teeling | — | — | |

FOREIGN PATENT DOCUMENTS

| INITIAL | INDEX | DOCUMENT | DATE | COUNTRY | CLASS | SUB. | TRANSLATION | |
|---------|-------|--------------|-------------|---------|-------|------|-------------|--|
| | | | | | | | | |
| WBS | D9 | 0 669 836 B1 | 7 Mar 1996 | EP | — | — | | |
| | D10 | 0 752 248 A1 | 8 Jan 1997 | EP | — | — | | |
| | D11 | 87/ 02671 A1 | 7 May 1987 | WO | — | — | | |
| | D12 | 89/ 00999 A1 | 9 Feb 1989 | WO | — | — | | |
| | D13 | 93/ 02108 A1 | 4 Feb 1993 | WO | — | — | | |
| | D14 | 00/ 27428 A1 | 18 May 2000 | WO | — | — | | |
| | D15 | 00/ 27433 A1 | 18 May 2000 | WO | — | — | | |
| | D16 | 01/ 10460 A1 | 15 Feb 2001 | WO | — | — | | |

| | |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 3/5/07 |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. | |
| Form PTO-1449 (modified) | SHEET 1 OF 5 |

| | | |
|--|--|------------------------|
| INFORMATION DISCLOSURE STATEMENT | Docket No. 27693-01009 | Serial No: 09/ 911,692 |
| | Inventor(s): D.R. ANDERSON <i>et al.</i> | Examiner: R. Schwadron |
| | Filed: 25 July 2001 | Art Unit: 1644 |


OTHER DOCUMENTS

| INITIAL | INDEX | CITATION |
|---------|-------|---|
| B3 | D17 | Anderson D.R. et al. <i>Biochem. Soc. Trans.</i> 25(2): 705-08, 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. |
| | D18 | Armitage J.O. et al. <i>J. Clin. Oncol.</i> 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. |
| | D19 | Berinstein N.L. et al. <i>Ann. Oncol.</i> 9: 995-1001, 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. |
| | D20 | Beychok S. (in) <i>Cells of Immunoglobulin Synthesis</i> , B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of <i>in vitro</i> and cellular assembly of immunoglobulins. |
| | D21 | Buchsbaum D.J. et al. <i>Cancer Res.</i> 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. |
| | D22 | Carrasquillo J.A. et al. <i>J. Nucl. Med.</i> 26: 67, abst. no. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody. |
| | D23 | Chinn P.C. et al. <i>Int. J. Oncol.</i> 15(5): 1017-25, Nov. 1999. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. |
| | D24 | Chinn P.C. et al. <i>Proc. Ann. Mtg. Am Assn. Cancer Res.</i> 40: 574, abst. no. 3786, 1999. A ⁹⁰ Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium. |
| | D25 | Cogliatti S.B. et al. <i>Sw. Med. Weekly</i> 192: 607-17, 2002. Who is <i>WHO</i> and what was <i>REAL</i> ? |
| | D26 | Davis T.A. et al. <i>Clin. Cancer Res.</i> 5(3): 611-15, 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. |
| | D27 | Davis T.A. et al. <i>Proc. Ann. Mtg. Amer. Assn. Cancer Res.</i> 39: 435, abst. no. 2964, 1998. Therapy of B cell lymphoma with anti-CD20 can result in relapse with loss of CD20 expression. |
| | D28 | Dillman R.O. <i>J. Clin. Oncol.</i> 12(7): 1497-1515, 1994. Antibodies as cytotoxic therapy. |

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED 3/5/00 |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. | |
| Form PTO-1449 (modified) | SHEET 2 OF 5 |


| | | |
|---|--|------------------------|
| INFORMATION DISCLOSURE STATEMENT | Docket No. 27693-01009 | Serial No: 09/ 911,692 |
| | Inventor(s): D.R. ANDERSON <i>et al.</i> | Examiner: R. Schwadron |
| | Filed: 25 July 2001 | Art Unit: 1644 |

| INITIAL | INDEX | CITATION |
|---------|-------|--|
| V31 | D29 | Grillo-López A.J. IBC Int'l. Conference on Antibody Engineering, La Jolla, December 1994. IDEC-C2B8 chimeric antibody and IDEC-Y2B8 radiolabeled antibody phase I and II studies in patients with non-Hodgkin's lymphoma (abstract of presentation). |
| | D30 | Grillo-López A.J. et al. <i>Ann. Oncol.</i> 7(3 Suppl.): 57, abst. no. 195, 1996. Treatment (rx) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti-CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT). |
| | D31 | Grillo-López A.J. et al. <i>Antibody Immunoconj. Radiopharm.</i> 8: 60, abst. no. 10, 1995. Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8. |
| | D32 | Grillo-López A.J. et al. <i>Blood</i> (86(10 Suppl. 1): 55a, abst. no. 207, 1995. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. |
| | D33 | Grillo-López A.J. et al. <i>Br. J. Haematol.</i> 93(Suppl. 2): 283, abst. no. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB): safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL). |
| | D34 | Horning S.J. et al. <i>Blood</i> 100(11 part 1): 357a, abst. no. 1385, 2002. Rituximab treatment failures: tositumomab and Iodine I 131 tositumomab (Bexxar®) can produce meaningful durable responses. |
| | D35 | IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for RITUXAN® approved by U.S. Food and Drug Administration on 26 November 1997. |
| | D36 | Janakirman N. et al. <i>Blood</i> 92(10 Suppl. 1): 337a, abst. no. 1384, Nov. 1998. Rituximab: correlation between effector cells and clinical activity in NHL. |
| | D37 | Kinoshita T. et al. <i>J. Clin. Oncol.</i> 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. |
| | D38 | Maloney D.C. et al. <i>Blood</i> 90(6): 2188-2195, 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. |
| | D39 | Maloney D.G. et al. <i>Blood</i> 88(10: Suppl. 1): 637a, abst. no. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. |




| | |
|--|--------------------|
| EXAMINER | DATE CONSIDERED |
|  | 3/5/07 |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. | |
| Form PTO-1449 (modified) | SHEET 3 OF 5 |


| | | |
|---|--|------------------------|
| INFORMATION DISCLOSURE STATEMENT | Docket No. 27693-01009 | Serial No: 09/ 911,692 |
| | Inventor(s): D.R. ANDERSON <i>et al.</i> | Examiner: R. Schwadron |
| | Filed: 25 July 2001 | Art Unit: 1644 |

| INITIAL | INDEX | CITATION |
|---------|-------|--|
| W3S | D40 | Maloney D.G. et al. <i>J. Clin. Oncol.</i> 15(10): 3266-3274, Oct. 1997. IDEC-C2B8: results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's Lymphoma. |
| | D41 | Maloney D.M. et al. <i>Blood</i> 84(8): 2457-66, 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. |
| | D42 | McLaughlin P. et al. <i>Blood</i> 92(10 Suppl. 1): 414a-415a, abst. no. 1712, Nov. 1998. Efficacy controls and long-term follow-up for relapsed or refractory, low-grade or follicular (R-LG/F) NHL. |
| | D43 | McLaughlin P. et al. <i>J. Clin. Oncol.</i> 16(8): 2825-2833, Aug. 1998. Rituximab chimeric-anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. |
| | D44 | McLaughlin P. et al. <i>Oncology</i> 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas. |
| | D45 | Non-Hodgkin's Lymphoma Pathologic Classification Project. <i>Cancer</i> 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. |
| | D46 | Pietersz G.A. et al. <i>Immunol. Cell. Biol.</i> 65(2): 111-25, 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. |
| | D47 | Piro L.D. et al. <i>Ann. Oncol.</i> 10: 655-61, 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. |
| | D48 | Press O.W. <i>Cancer J. Sci. Amer.</i> 4(Suppl 2): S19-S26, Jul. 1998. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. |
| | D49 | Teeling J.L. et al. <i>Blood</i> 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. |
| | D50 | Teeling J.L. et al. <i>J. Immunol.</i> 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. |
| | D51 | White C.A. et al. <i>Ann. Oncol.</i> 10(3 Suppl): 64, abst. no. 215, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC-Y2B8 phase I/II ⁹⁰ yttrium trial. |
| | D52 | White C.A. et al. <i>Ann. Rev. Med.</i> 52: 125-45, 2001. Antibody-targeted immunotherapy for treatment of malignancy. |
| ✓ | D53 | White C.A. et al. <i>Blood</i> 87(9): 3640-49, 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotype monoclonal antibodies. |

| | |
|--|-----------------|
| EXAMINER | DATE CONSIDERED |
|  | 3/5/07 |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. | |
| Form PTO-1449 (modified) | |
| SHEET 4 OF 5 | |

| | | | | |
|---|--------------|-----------------------------|------------|--------------|
| INFORMATION DISCLOSURE STATEMENT | Docket No. | 27693-01009 | Serial No: | 09/ 911,692 |
| | Inventor(s): | D.R. ANDERSON <i>et al.</i> | Examiner: | R. Schwadron |
| | Filed: | 25 July 2001 | Art Unit: | 1644 |

| INITIAL | INDEX | CITATION |
|---|-------|---|
|  | D54 | White C.A. et al. <i>Eur. J. Cancer</i> 35: S57, abst. no. 107, 1999. Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma. |
|  | D55 | Witzig T. et al. <i>Blood</i> 90(10 Suppl. 1): 586a, abst. no. 2606, 1997. IDEC-Y2B8 ⁹⁰ yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a phase I/II trial. |
| | D56 | Witzig T.E. et al. <i>J. Clin. Oncol.</i> 17(12): 3793-3803, 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. |
| | D57 | Witzig T.E. et al. <i>J. Clin. Oncol.</i> 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. |
|  | D58 | Witzig T.E. et al. <i>Blood</i> 94(10 Suppl. 1): 631a, abst. no. 2805, 1999. Prospective randomized controlled study of ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. |

| | |
|--|---------------------------|
| EXAMINER  | DATE CONSIDERED 3/5/07 |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. | |
| Form PTO-1449 (modified) | SHEET 5 OF 5 |